Updated:
GLAUKOS Corp
Glaukos develops ophthalmic pharmaceuticals and medical technologies for glaucoma, corneal disorders and retinal disease. Its commercial products…
Overview
Glaukos develops ophthalmic pharmaceuticals and medical technologies for glaucoma, corneal disorders and retinal disease. Its commercial products include iStent glaucoma devices and iDose TR, an implant designed to deliver glaucoma medication inside the eye; it also develops additional drug-delivery platforms. In its annual report, the company reported FDA approval of Epioxa for keratoconus in October 2025 and described plans at the time to begin commercialization in the first quarter of 2026.
Company overview
- Legal name
- GLAUKOS Corp
- Classification
- Public company
- SEC CIK
- 0001192448
- LEI
- 5299004JA1LHE21M6T14
- Website
- glaukos.com
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Revenue | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|---|
| FY2025USD | $507.4M | -$187.7M | $893.5M | $90.8M | -$14.8M |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research GLAUKOS Corp in Altss
Track this company’s investors, transactions and relationships in Altss.